<DOC>
	<DOCNO>NCT00645918</DOCNO>
	<brief_summary>The objective GRAVITAS trial determine whether tailored anti-platelet therapy use Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular event drug-eluting stent implantation .</brief_summary>
	<brief_title>GRAVITAS : Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Males female age 18 year old . 2 . Patients undergo coronary angiography possible PCI plan use least one drugeluting stent ( DES ) , without plan use glycoprotein IIb/IIIa inhibitor . One bare metal stent ( BMS ) may implant , lesion may treat without stenting , long least one DES implant . However , procedure must successful uncomplicated lesion ( DES + BMS + non stent ) . Indication procedure may stable angina ischemia , unstable angina , nonST elevation MI ( NSTEMI ) , ST elevation MI ( STEMI ) . Have ability understand requirement study , include consent use disclosure researchrelated health information . Have ability comply study procedure protocol , include require study visit . 6 . A female patient eligible enter study ( 1 ) childbearing potential pregnant nursing ; ( 2 ) childbearing potential ( i.e. , hysterectomy , ovary remove , tubal ligation , postmenopausal , define 24 month without menses ) . PrePCI PCI within previous 30 day . Prior consent participate GRAVITAS randomize IVRS . History gastrointestinal bleeding within 6 month . Major noncardiac surgery within 6 week . Ischemic stroke within 6 week . Any history hemorrhagic stroke subarachnoid hemorrhage . Other bleed diathesis , consider investigator highrisk bleed longterm clopidogrel therapy . Minor surgical procedure require cessation dual anti platelet therapy result significant bleeding NOT eligible . Current plan therapy coumadin anticoagulation . Current plan therapy thienopyridine class ADP receptor inhibitor ( e.g. , prasugrel , ticlopidine ) , nonthienopyridine ticagrelor . Severe allergy stainless steel , contrast dye , unfractionated heparin , low molecular weight heparin , bivalirudin adequately premedicated . Allergy aspirin clopidogrel . Current enrollment investigational drug device study reach time period primary endpoint . Have receive GPIIb/IIIa inhibitor eptifibatide tirofiban within 24 hour PCI abciximab within 10 day PCI . Thrombocytopenia ( define platelet count &lt; 100 K ) . Anemia ( hematocrit &lt; 30 % ) . Polycythemia ( hematocrit &gt; 52 % ) . Patients unwilling unable complete clinical followup duration study . PostPCI PCI placement least one DES perform . Planned stag PCI next 6 month postprocedure . Unsuccessful PCI ( postprocedure diameter stenosis &gt; 30 % less TIMI3 flow treat vessel ) . Patients inhospital STEMI confirm ECG prior randomization require target vessel revascularization index lesion prior randomization . Patients acute stent thrombosis Accumetrics VerifyNow test . Administration GPIIb/IIIa PCI procedure prior initial hospital discharge . Failure meet clopidogrel requirement Major complication PCI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Platelets</keyword>
	<keyword>Platelet Function Tests</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Drug Eluting Stents</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Stent Thrombosis</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Arterial Occlusive Disease</keyword>
</DOC>